714 related articles for article (PubMed ID: 23984729)
1. Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
Coelho T; Adams D; Silva A; Lozeron P; Hawkins PN; Mant T; Perez J; Chiesa J; Warrington S; Tranter E; Munisamy M; Falzone R; Harrop J; Cehelsky J; Bettencourt BR; Geissler M; Butler JS; Sehgal A; Meyers RE; Chen Q; Borland T; Hutabarat RM; Clausen VA; Alvarez R; Fitzgerald K; Gamba-Vitalo C; Nochur SV; Vaishnaw AK; Sah DW; Gollob JA; Suhr OB
N Engl J Med; 2013 Aug; 369(9):819-29. PubMed ID: 23984729
[TBL] [Abstract][Full Text] [Related]
2. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
[TBL] [Abstract][Full Text] [Related]
3. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.
Suhr OB; Coelho T; Buades J; Pouget J; Conceicao I; Berk J; Schmidt H; Waddington-Cruz M; Campistol JM; Bettencourt BR; Vaishnaw A; Gollob J; Adams D
Orphanet J Rare Dis; 2015 Sep; 10():109. PubMed ID: 26338094
[TBL] [Abstract][Full Text] [Related]
5. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
Yang J
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
Gillmore JD; Gane E; Taubel J; Kao J; Fontana M; Maitland ML; Seitzer J; O'Connell D; Walsh KR; Wood K; Phillips J; Xu Y; Amaral A; Boyd AP; Cehelsky JE; McKee MD; Schiermeier A; Harari O; Murphy A; Kyratsous CA; Zambrowicz B; Soltys R; Gutstein DE; Leonard J; Sepp-Lorenzino L; Lebwohl D
N Engl J Med; 2021 Aug; 385(6):493-502. PubMed ID: 34215024
[TBL] [Abstract][Full Text] [Related]
7. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
[TBL] [Abstract][Full Text] [Related]
9. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
Judge DP; Kristen AV; Grogan M; Maurer MS; Falk RH; Hanna M; Gillmore J; Garg P; Vaishnaw AK; Harrop J; Powell C; Karsten V; Zhang X; Sweetser MT; Vest J; Hawkins PN
Cardiovasc Drugs Ther; 2020 Jun; 34(3):357-370. PubMed ID: 32062791
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.
Goel V; Gosselin NH; Jomphe C; Zhang X; Marier JF; Robbie GJ
Nucleic Acid Ther; 2020 Jun; 30(3):143-152. PubMed ID: 32175804
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy.
Ackermann EJ; Guo S; Booten S; Alvarado L; Benson M; Hughes S; Monia BP
Amyloid; 2012 Jun; 19 Suppl 1():43-4. PubMed ID: 22494066
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/α-cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy.
Hayashi Y; Mori Y; Higashi T; Motoyama K; Jono H; Sah DW; Ando Y; Arima H
Amyloid; 2012 Jun; 19 Suppl 1():47-9. PubMed ID: 22519861
[TBL] [Abstract][Full Text] [Related]
15. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
[TBL] [Abstract][Full Text] [Related]
16. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
[TBL] [Abstract][Full Text] [Related]
17. Selective silencing of a mutant transthyretin allele by small interfering RNAs.
Kurosawa T; Igarashi S; Nishizawa M; Onodera O
Biochem Biophys Res Commun; 2005 Nov; 337(3):1012-8. PubMed ID: 16225852
[TBL] [Abstract][Full Text] [Related]
18. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte-Targeted Delivery of siRNA Polyplex with PEG-Modified Lactosylated Dendrimer/Cyclodextrin Conjugates for Transthyretin-Related Amyloidosis Therapy.
Hayashi Y; Higashi T; Motoyama K; Jono H; Ando Y; Onodera R; Arima H
Biol Pharm Bull; 2019; 42(10):1679-1688. PubMed ID: 31582656
[TBL] [Abstract][Full Text] [Related]
20. Vutrisiran: First Approval.
Keam SJ
Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
